| The challenges of organising cervical screening programmes in the 15 old member states of the European Union M Arbyn, M Rebolj, IMCM De Kok, M Fender, N Becker, M O’Reilly, ... European Journal of Cancer 45 (15), 2671-2678, 2009 | 219 | 2009 |
| Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review EEL Jansen, N Zielonke, A Gini, A Anttila, N Segnan, Z Vokó, U Ivanuš, ... European journal of cancer 127, 207-223, 2020 | 177 | 2020 |
| Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch … IMCM de Kok, J van Rosmalen, J Dillner, M Arbyn, P Sasieni, T Iftner, ... Bmj 344, e670, 2012 | 131 | 2012 |
| Cervical cancer screening in the United States and the Netherlands: a tale of two countries D Habbema, IMCM De Kok, ML Brown The Milbank Quarterly 90 (1), 5-37, 2012 | 107 | 2012 |
| Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands IMCM de Kok, M van Ballegooijen, JDF Habbema Journal of the National Cancer Institute 101 (15), 1083-1092, 2009 | 106 | 2009 |
| Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study CA Aitken, HME van Agt, AG Siebers, FJ van Kemenade, HGM Niesters, ... BMC medicine 17, 1-14, 2019 | 101 | 2019 |
| Cost‐effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing J van Rosmalen, I De Kok, M van Ballegooijen BJOG: An International Journal of Obstetrics & Gynaecology 119 (6), 699-709, 2012 | 98 | 2012 |
| Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004–2013 J van der Horst, AG Siebers, J Bulten, LF Massuger, IMCM de Kok Cancer medicine 6 (2), 416-423, 2017 | 84 | 2017 |
| Effects of cancer screening restart strategies after COVID-19 disruption LM Kregting, S Kaljouw, L de Jonge, EEL Jansen, EFP Peterse, ... British journal of cancer 124 (9), 1516-1523, 2021 | 78 | 2021 |
| Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates K Rozemeijer, C Penning, AG Siebers, SK Naber, SM Matthijsse, ... Cancer Causes & Control 27, 15-25, 2016 | 77 | 2016 |
| The potential of breast cancer screening in Europe N Zielonke, LM Kregting, EAM Heijnsdijk, P Veerus, S Heinävaara, ... International journal of cancer 148 (2), 406-418, 2021 | 76 | 2021 |
| Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? IMCM de Kok, MA van der Aa, M van Ballegooijen, S Siesling, ... International journal of cancer 128 (9), 2174-2181, 2011 | 75 | 2011 |
| Childhood social class and cancer incidence: results of the globe study IMCM De Kok, FJ Van Lenthe, M Avendano, M Louwman, JWW Coebergh, ... Social science & medicine 66 (5), 1131-1139, 2008 | 72 | 2008 |
| Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits? K Rozemeijer, IMCM de Kok, SK Naber, FJ van Kemenade, C Penning, ... Cancer Epidemiology, Biomarkers & Prevention 24 (5), 773-782, 2015 | 61 | 2015 |
| Predictors of HPV vaccination uptake: a longitudinal study among parents R Hofman, P van Empelen, JH Richardus, IMCM de Kok, HJ De Koning, ... Health education research 29 (1), 83-96, 2014 | 56 | 2014 |
| Gender differences in the trend of colorectal cancer incidence in Singapore, 1968–2002 IMCM de Kok, CS Wong, KS Chia, X Sim, CS Tan, LA Kiemeney, ... International journal of colorectal disease 23, 461-467, 2008 | 56 | 2008 |
| Cervical screening during the COVID-19 pandemic: optimising recovery strategies A Castanon, M Rebolj, EA Burger, IMCM de Kok, MA Smith, SJB Hanley, ... The Lancet Public Health 6 (7), e522-e527, 2021 | 54 | 2021 |
| Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study F Inturrisi, CA Aitken, WJG Melchers, AJC van den Brule, A Molijn, ... The Lancet Regional Health–Europe 11, 2021 | 48 | 2021 |
| Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis EW de Bekker-Grob, IMCM de Kok, J Bulten, J van Rosmalen, ... Cancer Causes & Control 23, 1323-1331, 2012 | 47 | 2012 |
| Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis EA Burger, IMCM De Kok, E Groene, J Killen, K Canfell, S Kulasingam, ... JNCI: Journal of the National Cancer Institute 112 (9), 955-963, 2020 | 45 | 2020 |
